According to ARRS' American Journal of Roentgenology, return to routine screening for BI-RADS 3 lesions on supplemental automated whole-breast ultrasound (ABUS) substantially reduces the recall rate, while being unlikely to result in adverse outcome. This prospective study supports a recommendation for routine annual follow-up for BI-RADS 3 lesions at supplemental ABUS.
